US2012156222A1PendingUtilityA1

Prevention and treatment of alzheimer's disease

57
Assignee: LANNFELT LARSPriority: Jul 7, 2000Filed: Mar 5, 2012Published: Jun 21, 2012
Est. expiryJul 7, 2020(expired)· nominal 20-yr term from priority
Inventors:Lars Lannfelt
A61P 37/04A61K 2039/505A61P 25/28A61P 25/16A61P 25/00C07K 14/4711A61K 38/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a purified antibody that specifically binds an α-synuclein protofibril.

Claims

exact text as granted — not AI-modified
1 . A purified antibody that specifically binds an a-synuclein protofibril. 
     
     
         2 . The antibody according to  claim 1 , wherein said antibody is monoclonal. 
     
     
         3 . The antibody according to  claim 1 , wherein said antibody is humanized. 
     
     
         4 . The antibody according to  claim 1 , wherein said antibody binds a mutant a-synuclein (Ala53Thr and Ala30Pro) protofibril. 
     
     
         5 . A method of preventing or treating an a-synuclein-related disorder, comprising the step of administering, to a patient having or suspected of having an a-synuclein-related disorder, the antibody according to  claim 1 . 
     
     
         6 . The method according to  claim 5 , wherein said alpha-synuclein-related disorder is selected from a group of disorders comprised of Parkinson's disease, dementia with Lewy Bodies, Lewy neuritis, Alzheimer's disease or Lewy Body Pathology.

Join the waitlist — get patent alerts

Track US2012156222A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.